Associated Press
Kai Klose, the health minister for Hesse state, which includes Frankfurt, said in a tweet that “several mutations typical of omicron” were found Friday night in a traveler returning from South Africa, who was isolated at home. Sequencing of the test had yet to be completed.
The global health body has named the new variant omicron, labeling it a variant of concern because of its high number of mutations and some early evidence that it carries a higher degree of infection than other variants. That means people who contracted COVID-19 and recovered could be subject to catching it again. It could take weeks to know if current vaccines are less effective against it.
With so much uncertainty about the omicron variant and scientists unlikely to flesh out their findings for a few weeks, countries around the world have been taking a safety-first approach, in the knowledge that previous outbreaks of the pandemic have been partly fueled by lax border policies.
Nearly two years on since the start of the pandemic that has claimed more than 5 million lives around the world, countries are on high alert.
The variant’s swift spread among young people in South Africa has alarmed health professionals even though there was no immediate indication whether the variant causes more severe disease.
A number of pharmaceutical firms, including AstraZeneca, Moderna, Novavax and Pfizer, said they have plans in place to adapt their vaccines in light of the emergence of omicron. Pfizer and its partner BioNTech said they expect to be able to tweak their vaccine in around 100 days.
Professor Andrew Pollard, the director of the Oxford Vaccine Group which developed the AstraZeneca vaccine, expressed cautious optimism that existing vaccines could be effective at preventing serious disease from the omicron variant.He said most of the mutations appear to be in similar regions as those in other variants.
“That tells you that despite those mutations existing in other variants the vaccines have continued to prevent serious disease as we’ve moved through alpha, beta, gamma and delta,” he told BBC radio. “At least from a speculative point of view we have some optimism that the vaccine should still work against a new variant for serious disease but really we need to wait several weeks to have that confirmed.”
He added that it is “extremely unlikely that a reboot of a pandemic in a vaccinated population like we saw last year is going to happen.”
Some experts said the variant’s emergence illustrated how rich countries’ hoarding of vaccines threatens to prolong the pandemic.
Fewer than 6% of people in Africa have been fully immunized against COVID-19, and millions of health workers and vulnerable populations have yet to receive a single dose. Those conditions can speed up spread of the virus, offering more opportunities for it to evolve into a dangerous variant.
“One of the key factors to emergence of variants may well be low vaccination rates in parts of the world, and the WHO warning that none of us is safe until all of us are safe and should be heeded,” said Peter Openshaw, a professor of experimental medicine at Imperial College London.
